Systemic Therapy — Whole-Body Cancer Treatments

Systemic therapy encompasses any pharmacological treatment administered orally or intravenously that travels through the bloodstream to reach cancer cells across the entire body. It is designed to destroy primary tumours, eradicate microscopic metastatic deposits, or slow disease progression when cancer has spread beyond its original anatomical boundaries.

This modality includes classic cytotoxic chemotherapy, molecularly targeted therapy, immunotherapy, and endocrine treatments. It can be deployed neoadjuvantly to shrink tumours prior to surgical intervention, adjuvantly to eliminate residual micrometastatic disease post-resection, or as definitive management for advanced, recurrent, or metastatic malignancies.

Understanding systemic therapy helps patients appreciate why particular medications are prescribed even after a surgeon has successfully excised a visible tumour. It allows individuals to anticipate whole-body side effects—such as fatigue, alterations in blood counts, digestive changes, or skin reactions—which differ distinctly from the localised side effects of surgery or targeted radiation. Discussing systemic options empowers patients to participate in shared decision-making regarding treatment schedules, administration routes, and quality-of-life considerations throughout their care trajectory.

Before commencing systemic therapy, baseline blood counts, renal function panels, and liver enzymes are evaluated to ensure the body can safely process the medications. Specific biomarkers—such as HER2 status, EGFR mutations, BRAF alterations, or PD-L1 expression—are assessed via tissue biopsy or liquid biopsy to select the most effective systemic agent.

Systemic therapy is utilised across virtually all cancer types. It is standard care for haematological malignancies like leukaemia and lymphoma, which are inherently systemic. It is also central to the management of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, and advanced melanoma.

Systemic therapy connects closely with multimodal treatment plans. It can precede surgery to downstage locally advanced tumours or follow surgical resection to eradicate micrometastatic disease. Furthermore, it is frequently combined simultaneously with radiotherapy (chemoradiation) to sensitise malignant cells and enhance local tumour control.